NEW YORK–(BUSINESS WIRE)–Tortoise Acquisition Corp. (the “Company”) today announced the pricing of its initial public offering (“IPO”) of 22,500,000 units at a price of $10.00 per unit. The units will […]

Unicorn IPO Report also reveals “herd mentality” among unicorn companies in stock class structure, board structure and composition, time-to-market, and executive compensation disclosure RESTON, Va.–(BUSINESS WIRE)–Unicorn companies went public at […]

NEW YORK–(BUSINESS WIRE)–Tortoise Acquisition Corp. (the “Company”) announced today that it intends to commence its initial public offering of 22,500,000 units at $10.00 per unit. The Company intends to grant […]

NEW YORK–(BUSINESS WIRE)–RMG Acquisition Corp. (the “Company”) announced today the closing of the issuance of an additional 3,000,000 units pursuant to the full exercise of the underwriters’ over-allotment option in […]

NEW YORK–(BUSINESS WIRE)–Axiom Global Inc. today announced it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) relating to the proposed […]

SAN FRANCISCO–(BUSINESS WIRE)–Levi Strauss & Co. (LS&Co.) today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a […]

Virgin Trains USA, which has plans to expand the Brightline rail in Florida, has postponed its IPO, a sign of restraint in an IPO market that had recently thawed. The […]

SAN DIEGO–(BUSINESS WIRE)–Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the […]

In an interview with Real Vision, IPO Edge Editor-in-Chief John Jannarone lays out several 2019 catalysts for luxury-theater operator iPic and clears up confusion created by uniformed short sellers. Chief […]

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Harpoon Therapeutics, Inc. (“Harpoon”), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today the pricing of its initial public offering of […]